- Home
- OPAD vs ME Comparison
OPAD vs ME Comparison
Compare OPAD & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- ME
- Stock Information
- Founded
- OPAD 2015
- ME 2006
- Country
- OPAD United States
- ME United States
- Employees
- OPAD N/A
- ME N/A
- Industry
- OPAD Real Estate
- ME Precision Instruments
- Sector
- OPAD Finance
- ME Health Care
- Exchange
- OPAD Nasdaq
- ME Nasdaq
- Market Cap
- OPAD 70.1M
- ME 68.4M
- IPO Year
- OPAD N/A
- ME N/A
- Fundamental
- Price
- OPAD $2.24
- ME $2.42
- Analyst Decision
- OPAD Hold
- ME Hold
- Analyst Count
- OPAD 6
- ME 1
- Target Price
- OPAD $5.19
- ME $9.40
- AVG Volume (30 Days)
- OPAD 47.0K
- ME 235.7K
- Earning Date
- OPAD 02-24-2025
- ME 01-28-2025
- Dividend Yield
- OPAD N/A
- ME N/A
- EPS Growth
- OPAD N/A
- ME N/A
- EPS
- OPAD N/A
- ME N/A
- Revenue
- OPAD $985,005,000.00
- ME $208,775,000.00
- Revenue This Year
- OPAD N/A
- ME $22.00
- Revenue Next Year
- OPAD $36.48
- ME $17.31
- P/E Ratio
- OPAD N/A
- ME N/A
- Revenue Growth
- OPAD N/A
- ME N/A
- 52 Week Low
- OPAD $2.08
- ME $2.42
- 52 Week High
- OPAD $9.30
- ME $13.74
- Technical
- Relative Strength Index (RSI)
- OPAD 42.40
- ME 32.49
- Support Level
- OPAD $2.21
- ME $2.42
- Resistance Level
- OPAD $2.49
- ME $2.96
- Average True Range (ATR)
- OPAD 0.18
- ME 0.19
- MACD
- OPAD 0.04
- ME 0.01
- Stochastic Oscillator
- OPAD 34.04
- ME 0.00
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.